Medicare GLP-1 Bridge Wegovy Pill: Who Qualifies for $50 a Month?

Medicare GLP-1 Bridge Wegovy pill coverage is real. Starting July 1, 2026, this temporary Medicare program can cover the Wegovy pill — the new once-daily tablet — for a flat $50 a month, if you qualify. It also covers the Wegovy shot, the Zepbound KwikPen, and Foundayo. Here’s the catch most people miss: this is not your normal Part D coverage, and one very common situation can actually disqualify you. Below is exactly who qualifies, what the $50 really pays for, and the next step to take.

Source: Centers for Medicare & Medicaid Services (CMS), Medicare GLP-1 Bridge program pages and payer sheet. Full sources at the bottom.

Which Medicare GLP-1 Bridge path is actually yours?

Quick answer: The Medicare GLP-1 Bridge is one of three different ways people pay for a GLP-1 like Wegovy: the Bridge (for weight loss, if you qualify), regular Medicare Part D (for diabetes, heart-risk, or sleep apnea uses), and cash-pay programs (for people without coverage). Most denials and confusion come from a person trying the wrong path for their situation. The table below shows which path most likely fits you.

We built this because the single biggest mistake we see isn’t “Medicare won’t cover it.” It’s people using the wrong door — and getting a denial that makes them give up. Find your row first.

Source: CMS Medicare GLP-1 Bridge beneficiary, provider, and pharmacy pages.

Does the Medicare GLP-1 Bridge cover the Wegovy pill?

Quick answer: Yes. CMS lists “Wegovy (injection and tablets)” among the drugs eligible through the Medicare GLP-1 Bridge, but only for people prescribed it for weight management who meet the program’s coverage and medical rules. “Wegovy pill” means Wegovy tablets — the once-daily oral form of semaglutide approved by the FDA in December 2025 — not compounded semaglutide and not a manufacturer coupon.

Let’s be precise about the words, because the confusion starts here. The Wegovy pill is oral semaglutide — a once-daily tablet. The FDA approved it on December 22, 2025, making it the first GLP-1 pill cleared for weight management (Novo Nordisk). It’s the same medicine family as the weekly Wegovy shot, just swallowed instead of injected.

Through the Bridge, here’s what’s in and what’s out on the Wegovy side:

For the Bridge to actually pay, four things all have to be true:

1. You have an eligible Medicare drug plan (a standalone Part D plan, or a Medicare Advantage plan that includes drug coverage).
2. The prescription is for weight management (not diabetes, not sleep apnea — more on that below).
3. You meet CMS’s medical rules (the three tiers in the next section).
4. A prior authorization — that’s your doctor’s request for approval — gets approved through the program.

Miss any one of those four, and the answer flips from “yes” to “not this way.” That’s not a reason to give up. It’s a reason to know which box you’re missing — which is the whole point of this page.

Who qualifies for the Wegovy pill through the Bridge?

Quick answer: Qualifying takes two things: the right kind of Medicare drug coverage, and a medical reason that fits one of three CMS categories. The categories are based on your body mass index (BMI) and certain health conditions, measured at the time you first started a GLP-1 — which matters for people who have already lost weight.

Gate 1 — Your Medicare drug coverage

You need Medicare drug coverage, not just hospital and doctor coverage. Here’s how the common situations shake out, per CMS:

CMS specifically leaves out Private Fee-for-Service plans, Section 1876 cost plans, health care prepayment plans, PACE, and a few others — unless you’re also enrolled in an eligible standalone Part D plan. And one relief built into the design: your Part D plan doesn’t have to “opt in.” CMS runs the Bridge through a single central processor, so your access doesn’t depend on your insurance company choosing to participate.

Gate 2 — The three medical paths

You only need to meet one of these three. CMS checks your BMI as of the day you first started GLP-1 therapy.

Source: CMS Medicare GLP-1 Bridge eligibility criteria.

Everyone also has to be 18 or older, on a qualifying plan, and prescribed the drug for weight management with a plan for lifestyle changes (nutrition and activity), which the FDA label calls for anyway.

“I already lost weight — did I lose my eligibility?”

This is one of the most common fears, and the answer is reassuring. No — losing weight doesn’t automatically knock you out. CMS measures the BMI rule at the point you started GLP-1 therapy, not where you are today. So if you began at a BMI of 37 and you’re now at 33, you can still fit Path 1 — as long as your doctor documents that starting number. The fix is simple: make sure your starting BMI is in your chart. For the full breakdown, see our Medicare GLP-1 Bridge eligibility guide.

What does the $50 really cost you? (And the one honest catch)

Quick answer: If you’re approved, the Wegovy pill costs $50 per month through the Bridge, and that $50 stays the same all year. The honest drawback: because the Bridge runs outside normal Part D, the $50 does not count toward your yearly Part D out-of-pocket maximum, and the low-income subsidy (Extra Help) does not reduce it.

Here’s the one drawback we want you to hear from us, not discover at the pharmacy counter. The Bridge does not run through your normal Part D benefit. So if you were counting on a pricey medication to push you toward your yearly out-of-pocket cap — the point where Part D starts paying nearly everything — the Bridge won’t help you get there. And if you have Extra Help (the low-income subsidy, or “LIS”) that normally drops your copays to just a few dollars, that discount doesn’t apply here either. Your price is $50, period.

For most people, that’s still dramatically less than the alternative. Without any program, Wegovy’s list price runs more than $1,000 a month. So a flat $50 isn’t just cheaper — it’s predictable. No deductible to clear in January. No price jump partway through the year. The same $50 every month, because it sits outside the Part D phases entirely. For someone who’s been priced out for years, that predictability is the whole point.

A note on the “cheaper” cash prices you may have seen. Novo Nordisk runs self-pay programs for people paying out of pocket. As of June 3, 2026, through NovoCare the Wegovy pill runs $149/month for the 1.5 mg and 4 mg doses (the 4 mg price rises to $199/month after August 31, 2026) and $299/month for the 9 mg and 25 mg doses. There’s also a savings card that can drop the price to as little as $25/month. But here’s the catch for Medicare readers: those self-pay prices and the savings card exclude people with government insurance like Medicare and Medicaid. That exclusion is exactly why the Bridge exists — it’s the Medicare-specific path, and at $50 it’s lower than the cash price anyway.

Cash and self-pay prices verified June 3, 2026 (NovoCare and Wegovy.com); they change often and exclude government-insured patients. The Bridge is the Medicare path.

Bridge vs. Part D: why the “wrong door” gets you denied

Quick answer: The Medicare GLP-1 Bridge and regular Medicare Part D are two separate doors. The Bridge is for using a GLP-1 for weight loss. Part D is for using one for a different approved reason, like type 2 diabetes, sleep apnea, or heart-risk reduction. Sending a request through the wrong door can trigger a denial even when the right door would have said yes.

Picture two doors.

Door 1 — the Bridge. This is the weight-loss door. If you qualify, your doctor sends the request to Medicare’s central processor (run by Humana), not to your plan, and you pay $50.

Door 2 — regular Part D. This is the door for GLP-1s used for something other than weight loss. And here’s the twist that surprises people:

If you have type 2 diabetes, sleep apnea, or noncirrhotic MASH (a liver condition, short for noncirrhotic metabolic dysfunction-associated steatohepatitis), CMS says you’re supposed to use Door 2 — and that makes you ineligible for the Bridge, even if your BMI fits.

Read that again, because it’s the disqualifier nobody warns you about. The Bridge was built specifically for people who want a GLP-1 only to lose weight. If you have one of those other diagnoses, your GLP-1 goes through regular Part D for that condition instead. That can feel like bad news. Usually it isn’t — it often means a path is already open to you that doesn’t depend on a temporary program at all.

When a request gets denied, it’s frequently a door problem, not a “no”:

What your doctor needs to do (and a script you can copy)

Quick answer: The Bridge isn’t a coupon you turn on yourself. A medical provider has to prescribe Wegovy if it’s appropriate for you and submit the Bridge prior authorization to Medicare’s central processor — and CMS will not accept those requests before July 1, 2026. Your job is to come prepared so your provider can move quickly.

You don’t apply. Your doctor does. (One technical note for them: CMS says a prescriber doesn’t have to be enrolled in Medicare to write the prescription or submit the Bridge request — they just can’t be on the Medicare Preclusion List, a short list of providers barred from Medicare. Nearly every licensed clinician is clear on this.)

Your role is to make the visit easy. Bring these:

• Your Medicare card and your Part D or Medicare Advantage drug-plan card
• Your current medication list
• Your height and current weight
• If you’ve taken a GLP-1 before: your starting BMI and the date you began
• Records for any qualifying condition (blood pressure readings, kidney labs, A1C or glucose, heart history, or leg-artery diagnosis)

Then hand them this. Copy it word for word:

“I’d like to know if I qualify for the Medicare GLP-1 Bridge for Wegovy when it starts July 1, 2026. Can we look at my starting BMI and any qualifying conditions, and whether Wegovy — the pill or the shot — is appropriate for me? If I fit the criteria, can your office submit the Bridge prior authorization to the CMS central processor, rather than a regular Part D weight-loss request?”

That last sentence matters. It steers your provider to the right door from the start — and saves you a denial. Want the deeper, step-by-step version of how providers submit and what the timeline looks like? We keep a full walkthrough on our Medicare GLP-1 Bridge application process guide, and a rundown of which clinicians can submit on our Bridge providers guide.

If your pharmacy claim gets stuck (the billing details that fix it)

Quick answer: Because the Bridge runs outside normal Part D, the pharmacy has to bill it through a special route — not your regular plan. CMS has published the billing identifiers on its official payer sheet: the group is GLP1Bridge, the BIN (the pharmacy’s routing number) is 028918, and the PCN (a secondary processor code) is MEDDGLP1BR, with claims handled by SS&C Health through RelayHealth, effective July 1, 2026.

Sometimes the prescription is approved but the pharmacy claim still bounces. That’s almost always a routing issue — the claim went to your normal plan instead of the Bridge. These are the details, straight from CMS’s official payer sheet (the technical instruction sheet pharmacies use):

Source: CMS GLP-1 Bridge payer sheet (NCPDP, dated March 16, 2026).

A few things to have ready and to know:

• Your Medicare card. The pharmacy needs your Medicare Beneficiary Identifier — the Medicare Number printed on your red, white, and blue Medicare card. If you don’t have it on you, the pharmacy can look the number up.
• That help-desk number is for the pharmacist, not for you. 844-673-0910 is a claims-processing line. If you have a coverage question, call 1-800-MEDICARE or your plan.
• Don’t pay full price hoping for a refund. CMS says the program doesn’t accept paper claims or mail-in member reimbursements — the claim has to run electronically through the Bridge. So if it won’t go through, fix the routing rather than paying cash and trying to get reimbursed later.

If your claim won’t go through after approval, this is the message for the pharmacist:

“This may be a Medicare GLP-1 Bridge prescription, not a standard Part D claim. Once the prior authorization is approved, can you check whether it should route through GLP1Bridge using BIN 028918 and PCN MEDDGLP1BR, and confirm the right NDC for the exact Wegovy tablet being dispensed?”

One compliance point worth stating plainly: compounded GLP-1 medications are not covered through the Bridge. CMS’s payer sheet marks the compound field as “1 = not a compound.” Compounded products are not FDA-approved finished drugs, and they don’t qualify for this pathway.

CMS has said it will release more operational guidance on pharmacy claims before launch, so we re-check these details monthly until July 1. Pharmacists should always confirm against the current CMS payer sheet.

Already prescribed Wegovy and got denied? Here’s what likely happened

Quick answer: A denial before July 1, 2026 usually means the Bridge simply wasn’t open yet. A denial after that often means the claim went through the wrong door, or that documentation was missing. And if a manufacturer savings card was rejected, that’s expected — those offers exclude people with government insurance, which is exactly why the Bridge exists.

Here’s the pattern we see again and again, especially right now in the weeks before launch: a doctor prescribes the new Wegovy pill, the pharmacy runs it through Medicare, it’s rejected — and then the patient tries the manufacturer’s savings card and gets told they’re not eligible “because they’re on Medicare.” None of that means the Wegovy pill is off the table.

That coupon rejection isn’t a glitch. Manufacturer savings cards — like Wegovy’s $25-a-month offer — exclude people with government insurance such as Medicare, Medicaid, and TRICARE. That’s not your plan being difficult; it’s how those offers are set up. The Bridge is the path built to fill exactly that gap.

Match your denial to its likely cause:

One honest note on what’s documented vs. what isn’t: the prescription-then-rejection-then-coupon-denial sequence above is a common point of confusion people describe online — not a coverage ruling. The rules on this page come from CMS and the FDA, not from forum posts.

Wegovy pill vs. the Wegovy shot: which should you ask for?

Quick answer: Both the Wegovy pill and the Wegovy injection are covered at $50 through the Bridge, so cost isn’t the deciding factor. In the pill’s main study, adults taking the 25 mg tablet lost about 13.6% of their body weight over 64 weeks, compared with about 2.4% on a placebo. That study compared the pill to a placebo — not directly to the shot — so your prescriber should decide which form fits you.

Since both cost the same $50, this comes down to fit, not price.

The shot (Wegovy injection) is once a week.

The pill (Wegovy tablets) is once a day — but it has rules. Per the FDA label, you take it first thing in the morning on an empty stomach, with no more than 4 ounces of water and nothing else to drink, and you wait at least 30 minutes before eating, drinking, or taking other pills. Skip that routine and your body absorbs much less of it.

On results: in the pill’s main trial — which the FDA label calls Study 7 — adults with obesity or overweight (people with type 2 diabetes were excluded) who took the 25 mg tablet lost about 13.6% of their body weight over 64 weeks, versus about 2.4% on placebo. Two honest caveats: that trial measured the pill against a placebo, not head-to-head against the shot, and the FDA label notes only that the blood levels of the drug from the daily 25 mg pill are predicted to be similar to the weekly 2.4 mg shot — a statement about drug levels, not a weight-loss comparison. Bottom line: both are real options, and which one is right is a medical decision for you and your prescriber.

How the pill steps up: it starts low and increases every 30 days — 1.5 mg, then 4 mg, then 9 mg, then 25 mg as the maintenance dose (FDA label). Your doctor manages that schedule.

What the Bridge does not cover

Quick answer: The Bridge covers a specific short list: Wegovy tablets and injection, the Zepbound KwikPen, and Foundayo, all for weight loss. It does not cover Ozempic, Rybelsus, or Mounjaro; it does not cover Zepbound vials or single-dose pens; and it does not cover any compounded GLP-1.

It helps to know the boundaries so you don’t chase a dead end:

If you’re on Ozempic, Rybelsus, or Mounjaro for type 2 diabetes, that’s a regular Part D matter — ask your plan about coverage for that use. And to be completely clear on the compliance point: compounded GLP-1s are not FDA-approved finished drugs, and they are not part of this Medicare pathway.

What happens after December 2027?

Quick answer: The Bridge is confirmed to run from July 1, 2026 through December 31, 2027. It was meant to hand off to a longer-term program called the BALANCE Model in 2027, but on April 21, 2026 CMS announced it would not launch BALANCE in Medicare for 2027 and extended the Bridge instead. What happens for Medicare after 2027 is not yet settled.

Let’s be straight with you, because this is the part that deserves honesty over hype. The Bridge runs 18 months — July 1, 2026 through December 31, 2027. That part is locked in (CMS). It was originally going to end at the close of 2026 and be replaced by a longer-term program called BALANCE. Then, on April 21, 2026, CMS announced it would not roll out BALANCE in Medicare for 2027, and extended the Bridge to fill the gap (CMS; KFF). Reporting suggests major Part D plans were reluctant to take on the BALANCE design as written (KFF).

So here’s the real risk, stated plainly: as of now, there is no confirmed Medicare coverage path for these drugs after December 31, 2027. Unless CMS extends the Bridge again or launches BALANCE for 2028, beneficiaries could face a coverage cliff in 2028 (KFF). We’re not telling you that to scare you off a great 18-month deal — we’re telling you so you and your doctor can plan for continuity before the calendar runs out. Watch for announcements during the fall 2027 enrollment period. (We track this on our BALANCE Model guide and update it as the picture changes.)

If you’re not on Medicare (or can’t use the Bridge yet)

Quick answer: The Bridge is Medicare-only and weight-loss-only. If you don’t have Medicare, don’t have an eligible drug plan, or need access before July 1, 2026, the Bridge isn’t your route — and you should not change your Medicare coverage based on a single article. Cash-pay telehealth is a separate option for people who aren’t using Medicare.

A few honest off-ramps:

If you have Medicare but no eligible drug plan, don’t make plan changes on your own — some Medicare Advantage switches can create new problems. Call 1-800-MEDICARE, your plan, or your free local SHIP counselor first.

If you’re not on Medicare — maybe you’re helping an adult child, or you’re not yet 65 — a cash-pay telehealth program can be a reasonable way to get an FDA-approved GLP-1 outside of insurance. One option to research is Ro, which focuses on FDA-approved branded medications and offers help navigating private insurance. Two things to keep straight: Ro is a private program, separate from the Medicare GLP-1 Bridge, and it doesn’t process Medicare coverage for GLP-1s. Government-insurance rules differ by program and can change, so if you have Medicare, Medicaid, or TRICARE, check Ro’s current terms directly before assuming you can or can’t use it. For people paying cash, Ro’s membership starts at $39 for the first month, then $149/month — or as low as $74/month with an annual plan paid upfront (medication is billed separately; verify current pricing before relying on it).

Your next steps if you want the Wegovy pill through the Bridge

Quick answer: Start with the path, not the product. Confirm your drug plan, gather your starting BMI and any qualifying condition, ask your doctor if Wegovy is right for you, plan for the Bridge prior authorization on or after July 1, 2026, and make sure your pharmacy routes the claim through the Bridge once it’s approved.

Five steps, in order:

1. Confirm you have an eligible Part D or MA-PD drug plan.
2. Find your tier — match your starting BMI and any condition to Path 1, 2, or 3.
3. Ask your doctor whether Wegovy (pill or shot) is appropriate for you.
4. Plan the prior authorization for on or after July 1, 2026 — your doctor sends it to the CMS central processor.
5. Hand the pharmacy the billing details (BIN 028918 / PCN MEDDGLP1BR) once you’re approved.

You don’t have to figure out all five today. You just have to take the first one. If you want a head start on matching providers and insurance, see our Wegovy pill providers that accept insurance guide.

How we verified this page

Quick answer: This page is built from primary and authoritative sources — CMS’s official Medicare GLP-1 Bridge pages and payer sheet, FDA-approved prescribing information, Novo Nordisk’s announcements and price guide, and KFF’s Medicare policy analysis. Our recommendations are based on those facts, never on affiliate payouts.

What we actually verified (June 3, 2026):

• Bridge start and end dates (July 1, 2026 – December 31, 2027) — CMS
• $50 monthly copay and that it’s your total cost — CMS
• The Bridge runs outside normal Part D — CMS
• The $50 doesn’t count toward your Part D out-of-pocket cap; Extra Help doesn’t lower it — CMS / KFF
• Eligible plan types and the three medical tiers — CMS
• BMI measured at the time GLP-1 therapy started — CMS
• Eligible drugs and forms: Wegovy (tablets and injection), Zepbound KwikPen only, Foundayo — CMS
• Pharmacy billing route: group GLP1Bridge, BIN 028918, PCN MEDDGLP1BR, SS&C/RelayHealth; no paper claims or member reimbursements — CMS payer sheet (dated 3/16/2026) and pharmacy guidance
• A prescriber needn’t be Medicare-enrolled but can’t be on the Preclusion List — CMS provider guidance
• Compounded products are not allowed — CMS payer sheet
• Wegovy pill FDA approval, dosing, the Study 7 result (≈13.6% vs ≈2.4% placebo over 64 weeks), and safety warnings — FDA prescribing information (revised 02/2026)
• Self-pay pricing: NovoCare lists the Wegovy pill at $149/mo (1.5 & 4 mg; 4 mg rises to $199/mo after Aug 31, 2026) and $299/mo (9 & 25 mg); the $25 savings card and these self-pay prices exclude government-insured patients — NovoCare / Wegovy.com
• BALANCE delayed for Medicare in 2027; Bridge extended; no confirmed path after 2027 — CMS / KFF
• Watch: CMS operational/pharmacy guidance expected before the July 1 launch — recheck monthly until then

The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. Some pages contain affiliate links, but affiliate relationships never decide whether we call a Medicare rule covered, excluded, or uncertain. For this guide, CMS and the FDA control the answer.

Frequently asked questions

Sources

• CMS — Medicare GLP-1 Bridge (overview & FAQs): https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
• CMS — Information for Medicare Beneficiaries: https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-medicare-beneficiaries
• CMS — Information for Providers: https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
• CMS — Information for Pharmacies: https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-pharmacies
• CMS — GLP-1 Bridge Payer Sheet (PDF, dated 3/16/2026): https://www.cms.gov/files/document/glp-1-bridge-payer-sheet.pdf
• CMS — BALANCE Model: https://www.cms.gov/priorities/innovation/innovation-models/balance
• KFF — What to Know About the BALANCE Model and the Medicare GLP-1 Bridge: https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/
• FDA — Wegovy Prescribing Information (revised 02/2026): https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s033lbl.pdf
• Novo Nordisk — Wegovy pill approved in the US (Dec 22, 2025): https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916472
• Novo Nordisk — Wegovy access via the Medicare GLP-1 Bridge (PR Newswire, May 7, 2026): https://www.prnewswire.com/news-releases/wegovy-access-expanded-for-medicare-beneficiaries-living-with-obesity-through-the-medicare-glp-1-bridge-starting-july-1-2026-302764949.html
• NovoCare / Wegovy — cost and self-pay pricing: https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html
• Ro — Weight Loss Program and Insurance: https://ro.co/weight-loss/insurance/